1168
1168
1286
1286
1297
1297
1200
1200
1401
1401
1440
1440
1502
1502
1467
1467
1521
1521
1095
1095
2019
2010
Company (27.9K)University (934)Hospital (270)Research Institution (202)Investor (36)Foundation (33)Other (1)
1 - 10 of 27,959
Sort by
Clinical Trial
Clinical Trial IDNCT04367311Start Date2020-06-01Completion Date2024-01-01PhasePhase 2Study TypeInterventionalStatusNot yet recruiting
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select IIIA) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy. However, relapse rates remain high and are primarily due to distant, metastatic disease. Previous meta-analysis evaluating the use of neo-adjuvant chemotherapy and adjuvant chemotherapy demonstrate a similar impact on improved disease free survival (DFS) and overall survival (OS). The role of checkpoint inhibitors has been proven to b…
Patent
Publication NumberUS 20200157235Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-07-10Publication Date2020-05-21
The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
Patent
Publication NumberUS 20200157635Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-10-03Publication Date2020-05-21
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention is based, at least in part, on the discovery that an immune-score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1…
Patent
Publication NumberUS 20200155520Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-11-13Publication Date2020-05-21
Provided herein are therapies including dosage regimens for the treatment of cancer using B-RAF and an immune checkpoint inhibitor in combination with and/or without a MEK inhibitor.
Patent
Publication NumberUS 20200155701Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2020-01-30Publication Date2020-05-21
The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®.
Patent
Publication NumberUS 20200157238Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-08-06Publication Date2020-05-21
The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprisi…
Patent
Publication NumberUS 20200157240Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-11-26Publication Date2020-05-21
This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
Patent
Publication NumberUS 20200155676Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-06-26Publication Date2020-05-21
The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.
Patent
Publication NumberUS 10653779Filing StatusIssued PatentAvailabilityUnknownFiling Date2014-03-13Publication Date2020-05-19
The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.
Patent
Publication NumberUS 10654932Filing StatusIssued PatentAvailabilityUnknownFiling Date2016-10-27Publication Date2020-05-19
The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
We found 27,959 documents that match your Search
Research Grants: 62
Patents: 26,134
Clinical Trials: 1,643
SEC Filings: 120

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in